scil

ArtisanArtisan Coral BioNetCoral BioNet

Scil Finance Holding GmbHScil Finance Holding GmbH

Scil Technology Holding GmbHScil Technology Holding GmbH

ScilAnimal Care

ScilAnimal Care

ScilDiagnostics

ScilDiagnostics

ScilBiomedicals

ScilBiomedicals

ScilProteins

ScilProteins

BioNetLaboratories

Asia Diagnostics

BioNetLaboratories

Asia Diagnostics

The SCIL Group

Stefan Engelhorn

20 % 80 %

scil

Scil Technology Holding

• Use niches in Life Science to develop, manufacture and marketinnovative diagnostics and therapeutics

• Use investment possibilities to synergize the existing operativebusiness

• Bridge the gap between VC funded companies and big pharmaby using professional industrial development know how

• Create profit along the value chain for our partners and ourselves

scil

Scil Technology Holding: ObjectivesShort term (3 years):

Focus on industrial know how to develop and market productsin diagnostics to generate short term cash flow.Partnerships with VC funded companies for co-development of innovative protein pharmaceuticals.

Medium term (3 - 6 years):

Project pipeline for innovative diagnostics and protein pharmaceuticalsfocussed on niche indications. Co-development and co-marketingof protein pharmaceuticals and innovative diagnostics products.

Long term (> 6 years):

Use the synergistic potential of diagnostic and therapeutic activitiesto create integrated solutions for more efficient treatments in nicheindications

scil

Scil Technology Holding: Competencies

An one year old privately owned company which is actively involved in the development and marketing of diagnostics and therapeutics

Diagnostics• proprietary immunoassay technology and data transfer concept• innovative reagent packaging concept• sales organizations in Europe and Asia (Singapore)• food testing products

Therapeuticsfocus on the development of therapeutic proteins• anti-L-selectin : prevention of polytrauma clinical phase II• immunotoxin MDX-RA : prevention of secondary cataract (partner Medarex) clinical phase III• bispec. antibody MDX-210: treatment of prostate cancer (partner Medarex) clinical phase Ib

Use the synergistic potential of diagnostics and therapeuticsto create integrated health care concepts for niche indications

scil

Scil Group: Management TeamS. Engelhorn, Ph.D., M.D.

G. Schumacher, Ph.D.

J. Bornemann

C. Dony, Ph.D.

J. Feuerstein, Ph.D.

R. Schenk, Ph.D.

U. Martin, M.D.

CEO of Scil Finance Holding. President of Scil Technology Holding. Member and chairman of several trusts

CEO of Scil Technology Holding. 20 years of industrial experience in diagnostics and therapeutics. Former head of R&D at BM/Roche

Vice President, CFO of Scil Technology Holding. Former at KPMG, tax consultant and commercial director at Gebr. März AG and Leonard Moll AG.

Vice President, Research and Development of Scil Technology Holding.Former head of musculoskeletal disorders at BM/Roche, scientist atGenentech Inc.

CEO of Scil Diagnostics. Former global strategic project planning at BM/Roche. Focus: marketing, PSO organization management, partnership management

CEO of Scil Diagnostics. Former head of system development and leaderproject lab diagnostics at BM/Roche. Focus: system and technology concepts and implementation

CEO of Scil Pharmaceuticals. Former head of pharmacology and cardiovascular research at BM/Roche and senior scientist at Hoechst

scil

Scil Biomedicals: Mission

Scil Biomedicals

is a young privately owned company with the mission to use

professional industrial drug-developmentknow how

to develop, manufacture and market innovativebio-pharmaceuticals

scil

Scil Biomedicals: Corporate Profile

Founded in May 1999

Privately owned company

Subsidiary of Scil Technology Holding GmbH

Focus: development of protein pharmaceuticals; innovative products for niche indications

- specific treatments for cancer and inflammation - tissue regeneration: ophthalmic, bone and cartilage

scil

Scil BioMedicals: Facilities and people

• Location in Martinsried/ Munich

• Employees: 10 people (20 people by mid of 2000)

• 700 square ft. lab space, Gründerzentrum Martinsried

• 9000 square ft. lab- and office-space (3/2000)

scil

Scil Biomedicals : Core Management TeamCEO

U. Martin

former head of pharmacology and cardiovascular research at BM/Roche; senior scientist at Hoechst

Pre-clinicalResearchC. Dony

Biotechnology

U. Kohnert

PharmaceuticalSciencesR. Seidl

Non-clinicalDevelopment

U. Martin

ClinicalDevelopment

M. Beckert

Former head ofmusculoskeletaldisorders R&Dat BM/Roche;scientist at Genentech

project leaderbiotechnology for reteplase, specialist inpreformulationat BM/Roche

Former head ofpharmacology,project leader: therap. Mab`s, gene therapyat BM/Roche

Former head ofclinical researchat MSD

Team of legal (B. Jurisch), patent (B. Huber) and diagnostic (A. Wahlefeld) advisors

Project leader quality controlat Mucos pharma

scil

Scil Biomedicals: Core Competence

Development of protein pharmaceuticals

from active compound

to approval

scil

Scil Biomedicals: Core CompetenceDevelopment of protein pharmaceuticals

Protein bulk drug

Finished product

Integrated technology platform for bulk drug and finished product- protein process development- formulation/drug delivery- pharmaceutical analyses

Pre-clinic bioanalytics

Clinical development

Regulatory affairs

Experienced steering of non-clinical and clinicaldevelopment activities including GMP manufacturingvia CROs

Team of project leaders with experience in inter-national project development and regulatory filing (FDA & EMEA for RapiLysin®/RetavaseTM)

Approval

scil

Scil Biomedicals: Fast track development of Anti-L-Selectin (BNP 001) in 1999Anti-L-selectin for the prevention of multi organ failure (partner: PDL) after polytrauma

January 15

February 24

March 31

June 2

June 4

July 14

July 28

November

LETTER OF INTENT: PDL - BioNet for anti-L-selectin

Start TECHNICAL TRANSFER (know how, reports and materials)

CONTRACT PDL - BioNet signed

CLINICAL DRUG SUPPLIES released

PHASE I: first in man

DOSE SELECTION FOR PHASE II

Submission of phase II study protocol to CENTRAL ETHICS COMMITTEE of PI

PHASE II (Polytrauma): “first patient in”

scil

Scil Biomedicals: Strategic Focus

• Development of innovative protein pharmaceuticals • Antibodies and growth factors as specific therapies

for niche indications

Oncology, (tumor specific therapies)

Inflammation (multi organ failure)

Eye disorders

bone and cartilage disorders

scil

Scil Biomedicals: Research & DevelopmentPipeline

• Immunotoxin MDX-RA prevention of secondary cataract (partner Medarex)

- clinical phase III - market entry 2003

• Anti-L-selectin prevention of multi organ failure after severe polytrauma (partner: PDL)- clinical phase II- market entry 2003/4

• Bispecific antibody MDX-210 late stage prostate cancer (partner Medarex) - clinical phase Ib - market entry 2005

• research on growth factors for tissue regeneration eg. bone and cartilage disorders

scil

Scil Proteins

is a young privately owned company with the mission to use

professional scientific and industrial protein production know how

to develop and manufacture pharmaceutical proteins

Scil Proteins: Mission

scil

Development of pharmaceutical proteins

from design to production

of an active protein

Scil Proteins: Core competence

scil

Scil Proteins: Core technologies

Technologies/Services:

• Small scale production of recombinant proteins

• Refolding of E. coli inclusion body proteins samples for: preclinical research

protein structure analysis

rationale drug design

• Protein binding Molecule Technology

scil

Scil Proteins: Core competenceDevelopment of pharmaceutical proteins

Recombinant

protein production

Pro- and eukaryotic expression systems

Fermentation 10l, 50l, 100l reactors

Refolding of proteins frominclusion bodies

Proteinpurification conventional methods, affinity techniques

Physicochemical characterization CD, fluorescence, mass spectroscopy, biacore

Customized protein

folding

Isolation of stable

binding proteins Screening of scaffold phage display libraries

scil

Scil Proteins: Facilities and people

Scil Proteins: People and facilities

• Location in Halle/Saale

• Scientific founder Prof. R. Rudolph, Inst. of Biotechnology, Halle

• Employees: 6 people (12 people by end of 2000)

• 1000 square foot lab- and office-space associated with the Institute for Biotechnology

(3/2000)

• 4200 square foot lab- and office-space “Gründerzentrum Halle” (10/2000)

scil

Scil Protein Technology Services: Core Competence

• Expression systems (pro- and eukaryotic organisms)

• Fermentation facilities: 10 l-, 50 l-, 100 l-reactors (E. coli)

• Highly specialized protein refolding technology - automaticprotein folding reactor for proteins expressed in inclusionbodies (E. coli)

• Proteinpurification: conventional methods and affinity techniquesto guarantee straight forward purification of protein samples

• Physicochemical characterized and proteinprofiling, massspectroscopy, CD, fluorescence/biacore, protein sequencing,etc.

scil

Scil Protein Technology ServicesProjects of the Institute of Protein Technologies: Prof. R. Rudolph, HalleSuccessful refolding of inclusion body proteins expressed in E. coli

Protein

GLP1-Receptorpro NGFpro BMP2PTH-ReceptorProteinase KEnterokinasePepsinogenProcollagen C Proteinaseh Phosphodiesterase PDE 4HIV ProteaseAntibody fragmentsCD 4Helicase

Partnership

Boehringer MannheimBoehringer MannheimRocheRocheRocheGenetics InstituteSchweizer Rotes Kreuz / NovartisPfizerUniversity Leipzig / AWDUniversity Halle---